- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01000441
Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis (ROC)
August 5, 2021 updated by: University Hospital, Strasbourg, France
Approximately 30% of patients with rheumatoid arthritis have an inadequate response to anti-TNF (primarily or loss of response), leaving two alternatives: rotation to a second anti-TNF or change of biologic, with a different mechanism of action, such as abatacept, rituximab and tocilizumab.
No controlled trial compared these two strategies face to face.
The present objective is to investigate the issue whether one of these strategies could have a better efficacy in a pragmatic trial in the setting of current practice.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
300
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Amiens, France
- Polyclinique de Picardie
-
Belfort, France
- Centre Hospitalier de Belfort-Montbeliard
-
Besançon, France
- CHU de Besançon - Hôpital Jean Minjoz
-
Bondy, France
- Hôpital Jean Verdier
-
Bordeaux, France
- CHU Bordeaux - Hôpital Pellegrin
-
Boulogne - Billancourt, France
- Hopital Ambroise Pare
-
Brest, France
- CHU de la Cavale Blanche
-
Caen, France
- CHU de Caen
-
Cahors, France
- Centre Hospitalier Jean Rougie
-
Cannes, France
- Centre Hospitalier de Cannes
-
Clermont-Ferrand, France
- Chu Gabriel Montpied
-
Colmar, France
- Hopitaux Civils de Colmar
-
Grenoble, France
- CHU de Grenoble - Hôpital Sud
-
Kremlin Bicetre, France
- Hôpital Bicêtre
-
La Roche Sur Yon, France
- Centre Hospitalier Départemental Les Oudairies
-
Le Havre, France
- Groupe Hospitalier du Havre - Hôpital J.Monod
-
Le Mans, France
- Centre Hospitalier du Mans
-
Lievin, France
- Polyclinique de Riaumont
-
Lille, France
- CHRU Lille - Hôpital Salengro
-
Limoges, France
- CHU de Limoges
-
Lomme, France
- CH Saint Philibert
-
Marseille, France
- Hôpital de la Conception
-
Montpellier, France
- CHU de Montpellier - Hôpital Lapeyronie
-
Montpellier, France
- CHU Montpellier, Hopital Lapeyronie
-
Mulhouse, France
- Centre Hospitalier de Mulhouse - Hopital Emile Muller
-
Nantes, France
- CHU de Nantes - Hôtel Dieu
-
Nice, France
- CHU de Nice - Hôpital de l'Archet 1
-
Orleans, France
- Centre Hospitalier Régional d'Orléans, Hôpital de la Source
-
Paris, France
- Hôpital Saint-Antoine
-
Paris, France
- Hôpital Lariboisière
-
Paris, France
- Hopital Bichat
-
Paris, France
- Hopital de la Pitie Salpetriere
-
Paris, France
- CHU Chenevier - Mondor
-
Paris, France
- Groupe Hospitalier Diaconesses - Hôpital de la Croix Saint-Simon
-
Poitiers, France
- CHU de Poitiers - Hôpital de la Milétrie
-
Pontoise, France
- Centre Hospitalier Rene Dubos
-
Reims, France
- CHU de Reims - Hôpital Maison Blanche
-
Rennes, France
- CHU de RENNES - Hôpital Sud
-
Rouen, France
- CHU de Rouen - Hôpital Bois Guillaume
-
Saint-Etienne, France
- Chu de Saint-Etienne
-
Strasbourg, France
- Hopital de Hautepierre
-
Toulouse, France
- CHU de Toulouse - Hôpital Purpan
-
Vandoeuvre-les-nancy, France
- CHU de Nancy - Hôpital Brabois
-
-
-
-
-
Monaco, Monaco
- Centre Hospitalier - Princesse Grâce de Monaco
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Active and erosive rheumatoid arthritis with a DAS28 equal or greater than 3.2
- Inadequate response to a 1st anti-TNF
- Stable or no treatment with any DMARDs, or oral corticosteroids (< or = to 10 mg/day of prednisone equivalent)during the preceding month
Exclusion Criteria:
- Counter-indication to other anti-TNF, abatacept, rituximab or tocilizumab
- Pregnancy
- Age < 18 years
- Impossibility to give informed consent
- Impossibility to be followed for 12 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: arm 1 (2d anti-TNF):
infliximab, etanercept, adalimumab
|
|
Active Comparator: arm 2 (other biotherapy)
abatacept, rituximab or tocilizumab
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of EULAR responders
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jacques-Eric GOTTENBERG, MD, PhD, Hopitaux Universitaires de Strasbourg
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Nguyen MVC, Courtier A, Adrait A, Defendi F, Coute Y, Baillet A, Guigue L, Gottenberg JE, Dumestre-Perard C, Brun V, Gaudin P. Fetuin-A and thyroxin binding globulin predict rituximab response in rheumatoid arthritis patients with insufficient response to anti-TNFalpha. Clin Rheumatol. 2020 Sep;39(9):2553-2562. doi: 10.1007/s10067-020-05030-6. Epub 2020 Mar 24.
- Virone A, Bastard JP, Fellahi S, Capeau J, Rouanet S, Sibilia J, Ravaud P, Berenbaum F, Gottenberg JE, Sellam J. Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis. RMD Open. 2019 Jul 21;5(2):e000897. doi: 10.1136/rmdopen-2019-000897. eCollection 2019.
- Riviere E, Sellam J, Pascaud J, Ravaud P, Gottenberg JE, Mariette X. Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis. Arthritis Res Ther. 2018 Jun 8;20(1):122. doi: 10.1186/s13075-018-1628-6.
- Gottenberg JE, Brocq O, Perdriger A, Lassoued S, Berthelot JM, Wendling D, Euller-Ziegler L, Soubrier M, Richez C, Fautrel B, Constantin AL, Mariette X, Morel J, Gilson M, Cormier G, Salmon JH, Rist S, Liote F, Marotte H, Bonnet C, Marcelli C, Sellam J, Meyer O, Solau-Gervais E, Guis S, Ziza JM, Zarnitsky C, Chary-Valckenaere I, Vittecoq O, Saraux A, Pers YM, Gayraud M, Bolla G, Claudepierre P, Ardizzone M, Dernis E, Breban MA, Fain O, Balblanc JC, Aberkane O, Vazel M, Back C, Candon S, Chatenoud L, Perrodeau E, Sibilia J, Ravaud P. Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial. JAMA. 2016 Sep 20;316(11):1172-1180. doi: 10.1001/jama.2016.13512.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 23, 2009
Primary Completion (Actual)
August 12, 2013
Study Completion (Actual)
August 12, 2013
Study Registration Dates
First Submitted
October 22, 2009
First Submitted That Met QC Criteria
October 22, 2009
First Posted (Estimate)
October 23, 2009
Study Record Updates
Last Update Posted (Actual)
August 9, 2021
Last Update Submitted That Met QC Criteria
August 5, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Arthritis, Rheumatoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gastrointestinal Agents
- Antineoplastic Agents, Immunological
- Dermatologic Agents
- Immune Checkpoint Inhibitors
- Etanercept
- Adalimumab
- Rituximab
- Infliximab
- Abatacept
Other Study ID Numbers
- 4507
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Universidad Autonoma de Nuevo LeonCompletedRheumatoId ArthritisMexico
-
Hamad Medical CorporationUnknownRHEUMATOID ARTHRITISQatar
Clinical Trials on infliximab, etanercept, adalimumab
-
University Hospital, Gentofte, CopenhagenPfizer; The Michaelsen FoundationUnknown
-
University of PadovaUnknownModerate to Severe Psoriasis. | Absolute Number, Density of Immune Infiltrate and Dendritic Cells and Inflammatory Cytokines Expression Pattern.Italy
-
University of SulaimaniRecruitingRheumatoid Arthritis | Inflammatory Arthritis | Ankylosing SpondylitisIraq
-
Merck Sharp & Dohme LLCWithdrawn
-
University of AberdeenNHS GrampianCompleted
-
University of Sao PauloUnknownArthritis, Rheumatoid | Spondylitis, AnkylosingBrazil
-
University Hospital, MontpellierCompletedSpondyloarthritisFrance
-
University Hospital, GhentAbbottCompleted
-
Diakonhjemmet HospitalCompletedUltrasonography | SpondyloarthritisNorway
-
University of Erlangen-Nürnberg Medical SchoolCompleted